Cardiff Oncology UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
My name is DJ Zhang. I am on the healthcare investment banking team at UBS, and thank you again for coming to our inaugural conference. We are really excited to be starting this and hosting everyone here at the Rosewood. I am also excited to introduce Mani Mohindru, who is the CEO of Cardiff Oncology.
All right. Is my mic working? Yes. Thank you, DJ and the UBS team for inviting us to the conference and giving us the opportunity to tell our story. I will be telling you the value proposition in Cardiff, specifically as it relates to targeting colon cancer with pan-RAS mutations across the board, both NRAS, KRAS, with a very selective and tolerable PLK1 inhibitor that I will be showing some data from. I am also very pleased to report that we got Fast Track designation for this particular indication as well on Friday, and we put out the release this morning. I will be making forward-looking statements during this presentation, so please refer to our SEC filings for the risk factors.
This slide kind of summarizes what we believe is a significant opportunity, bringing a new class of drugs to be a potential treatment-changing paradigm in the treatment of patients with RAS-mutated metastatic colorectal cancer in the first-line setting. Hopefully, I can convince you, based on the efficacy data that I will be sharing with you, where we have had some very compelling efficacy trends we have seen in our randomized phase II trial controlled with the given chemo, the current chemo standard of care regimens, where we have shown around 70% plus overall response rate versus 42% or so that you see in the current standard of care arm, an almost 30% improvement versus the standard of care.
More importantly, while the median PFS data have matured in the control arm, the trial is ongoing, and we still have not reached median PFS in the 30 milligram plus FOLFIRI bev arm, acknowledging that the study was not quite powered for PFS. This is not just one trial where we have seen this efficacy. These data and this study, the study was built on a prior study where, again, we had shown compelling efficacy in the second line in bev-naive patients with this combination of chemo in RAS-mutated, in that particular study, which was KRAS-mutated population. We believe if we are successful in phase III, we have the potential to change practice and bring a new treatment to this disease where there has not been any kind of innovation for the last 20 years, and it remains an area of high and significant unmet need.
In addition to colon, we have also seen some very promising signals in chronic myelomonocytic leukemia, which interestingly is also, almost half the patients there are also ones that have RAS pathway-driven mutations. It is interesting to see the signals, and there we have seen it in single agent, in monotherapy. We have spent a good part of our year having regulatory interactions. We have had our End-of-Phase 2 meeting successfully with the FDA, which has led to us designing a phase III trial. We have picked our dose and the chemo regimen with the blessings of the agency, and we are working earnestly towards starting our phase III trial, and we have the potential to go for accelerated approval as well, based on ORR and some durability, as well as full approval based on PFS. This is what the current metastatic RAS population looks like, metastatic colorectal cancer patients.
Almost 50% of these patients have mutations in the RAS enzyme, and there are all kinds of mutations. With our PLK1 inhibitor, we are able to enroll any patient with any of these mutations, and the data that I will share in the subsequent slide shows that our PLK1 inhibitor has the potential to be beneficial across the board. Almost 50% of metastatic colorectal patients have RAS mutations. More interestingly, in the last 20-plus years, the only treatment available to these patients has been chemo, and then Avastin got added, which has now become generic as well. There has not been really any new treatment for these patients who tend to do much poorly than their wild-type counterparts. As you can see, the overall survival is not very good for these patients.
I just want to spend a little bit of time explaining why a PLK1 inhibitor in RAS-mutated disease. There has been some interesting research that has been done outside of Cardiff, which has shown that colon cancer specifically, the ones who harbor these RAS mutations, they rely heavily on PLK1 for cell division. In fact, PLK1 emerged as one of the first targets in a RNAi-based screen that was done in RAS-mutated colon cancers. Certainly, there is kind of a synthetic vulnerability here that we are addressing with our PLK1 inhibitor. The second thing is our drug, the PLK1 inhibitor, onvansertib, synergizes well with FOLFIRI, specifically irinotecan, a topoisomerase I inhibitor, not just in this study that I am going to share the data from, but also in a prior study.
It has some mechanistic basis for it, which is by inhibiting HIF-1 alpha, which is an important angiogenic mechanistic pathway that the cancers rely on. Both irinotecan as well as our PLK1 inhibitor inhibit HIF-1 alpha, which works along with bevacizumab, which is another agent that tackles angiogenesis. All these things together are able to block the angiogenesis pathways that are needed for cancers to grow. The next few slides would focus on data from our ongoing randomized phase II trial, CRDF-004 study. We have shared a big decision-making chunk of our data at ASCO. It was as part of our oral presentation that was done by our PI, Dr. Lenz, Heinz Joseph Lenz out of USC. In this particular case, we had the study so designed to pick a dose and a chemo regimen, which we did.
We have the 30 milligram onvansertib in combination with FOLFOXIRI bev that we would be taking into registrational trial. I have already shared the kind of compelling efficacy we see, both in terms of response rates as well as durability, that the data continue to mature in the onvansertib arm. We gave a little update recently that all patients who now are still on the 30 milligram onvansertib plus FOLFOXIRI arm have been on treatment for greater than 21 months. The median PFS has been reached in the standard of care arm, which is very similar, both standard of care FOLFOX and FOLFOXIRI arms, which is very similar to what has been historically reported at around 11 months. This is the design of the study.
This is a randomized control study where we were looking at two chemo regimens that are used in RAS-mutated population, a RAS-mutated mCRC population in the front line, FOLFOXIRI bev and FOLFOX bev. We picked two different doses as part of Project Optimus of the FDA to pick the best dose forward. Although going into the study, we knew that 30 milligram onvansertib was the best and optimal dose. We did prospectively select every patient for RAS mutations and made sure that there was no patient who had been previously exposed to bevacizumab. The dosing regimen works very well with the standard chemo regimens given.
We give the drug for days one through five, then there is a drug holiday for nine days, and then days 15 through 19 of a 28-day cycle, with the primary endpoint being overall response rate, objective response rate, and the secondary endpoints being durability, endpoints of duration of response, and progression-free survival. This slide just shows very typical baseline characteristics. It is nothing unusual here. The patients were all newly diagnosed metastatic colorectal patients with RAS mutations. There are a couple things I do want to highlight. We did not exclude patients with liver mets, so we had patients who had liver metastasis at study entry, and there were also patients who had multi-organ mets involvement. These are the kind of patients who have bad prognosis. They are amongst the worst patients that you can include in these studies.
I will share the data in the subsequent slides where you will see that our drug continues to show benefit even in these hard-to-treat patients. At ASCO in June, we presented data cut as of March 18th, and that is highlighted in the box there, the yellow box. There were 14 patients still on trial at that time, and 13 of those 14 patients were on some combination of onvansertib plus chemo. We have since given an update based off of what we are looking at at the end of September, and the data is still being cleaned, but we have eight patients who still continue to be on treatment. Importantly, only one patient still continues to be on standard of care, and three patients are on the 30 milligram arm, and rest of them between 20 milligram FOLFOXIRI or 20 milligram FOLFOX arm.
This just shows that onvansertib is doing something such that the patients on these onvansertib arms continue to be on treatment for a long period of time, while most of the patients on the standard of care arms have come off treatment. These are the waterfall plots that talk about how the treatment regimens of onvansertib standard of care or onvansertib plus standard of care benefits patients in terms of tumor reduction. I do not think I need to convince anyone about which panel looks like a clear winner. It is, of course, the onvansertib 30 milligram plus FOLFOXIRI bev arm, where we see an objective response rate of the order of 70+% versus 42%, what we see in the FOLFOXIRI bev arm.
Not only is the response rate high, but if you look at the depth of responses, they seem to be significantly better in the onvansertib 30 milligram arm in a dose-dependent manner from 20 to 30. If you move there, you not only get higher response rates, but you also get higher depth of responses. The arrowheads there show the patients who are still on treatment, and you can see majority of them lie in onvansertib plus FOLFOXIRI arm. The other thing to highlight here are these diamonds on the top. It is a small study, but you can see that numerically, there were more patients on the onvansertib 30 milligram plus FOLFOXIRI arm who went on to curative surgery. The drug treatment was able to shrink the tumors enough such that these patients could be put on curative surgery.
They left the study to get curative surgery, and they really were not contributing to the PFS analysis that we had done in this early-stage study. This, to me, is the most compelling slide. Certainly, this slide and the data on this slide gives us a lot of confidence as we move into phase III. These so-called spider plots not just show tumor shrinkage, but they show tumor shrinkage over time. Again, if you can see very clearly, on the right side panel, the panel on the rightmost side, onvansertib 30 milligram FOLFOXIRI, over time, you see that the tumors continue to shrink and they continue to be kept, the tumor shrinkage is maintained, versus the control arm, where you do get tumor shrinkage early on, but not very deep and not for very long.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
